Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities (2016 - 2026)
Viridian Therapeutics, Inc.\DE has reported Cash from Investing Activities over the past 12 years, most recently at -$339.4 million for Q4 2025.
- Quarterly results put Cash from Investing Activities at -$339.4 million for Q4 2025, down 439.49% from a year ago — trailing twelve months through Dec 2025 was -$37.6 million (up 83.57% YoY), and the annual figure for FY2025 was -$37.6 million, up 83.57%.
- Cash from Investing Activities for Q4 2025 was -$339.4 million at Viridian Therapeutics, Inc.\DE, down from $126.1 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for VRDN hit a ceiling of $126.1 million in Q3 2025 and a floor of -$339.4 million in Q4 2025.
- Median Cash from Investing Activities over the past 5 years was $7.6 million (2021), compared with a mean of -$27.5 million.
- Biggest five-year swings in Cash from Investing Activities: surged 11894.34% in 2021 and later crashed 975.93% in 2024.
- Viridian Therapeutics, Inc.\DE's Cash from Investing Activities stood at -$80.2 million in 2021, then crashed by 125.16% to -$180.6 million in 2022, then grew by 6.03% to -$169.7 million in 2023, then skyrocketed by 62.93% to -$62.9 million in 2024, then plummeted by 439.49% to -$339.4 million in 2025.
- The last three reported values for Cash from Investing Activities were -$339.4 million (Q4 2025), $126.1 million (Q3 2025), and $75.7 million (Q2 2025) per Business Quant data.